LINEAGE CELL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.1 USD | -3.51% |
|
-14.73% | +0.92% |
Presentation Operator MessageOperator (Operator)Welcome to the Lineage Cell Therapeutics Fourt...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.1
USD
Average target price
5.2
USD
Spread / Average Target
+372.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.92% | 207M | |
| +4.09% | 43.84B | |
| +46.96% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- LCTX Stock
- News Lineage Cell Therapeutics, Inc.
- Transcript : Lineage Cell Therapeutics, Inc., Q4 2021 Earnings Call, Mar 10, 2022
